Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.

Rybelsus is a glucagon-like peptide-1 (GLP-1) agonist available as a tablet. It is used to treat type 2 diabetes. Metformin ...

Rybelsus is a pill form version of semaglutide – an FDA approved prescribed medication to manage blood sugar levels in patients with type 2 diabetes. Another effect that Rybelsus has is that it can ...

The FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the first challenge facing the company as it pursues its blockbuster sales targets for ...

Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...